Avid Bioservices Inc (CDMO)

[dia76ca]

Tarvacin(TM) Equivalent Plus Radiation Therapy Reduces Tumor Growth by 98%

Monday November 8, 12:09 pm ET
Data Presented at Vascular Targeting Agent Conference in Cambridge, Massachusetts

TUSTIN, Calif., Nov. 8 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News) announced today that Philip Thorpe, Ph.D., a member of its scientific advisory board, gave the keynote presentation at the Vascular Targeting Agents conference in Cambridge, Massachusetts. Dr. Thorpe's address highlighted a growing body of pre-clinical evidence supporting the development of Vascular Targeting Agents (VTAs), which are designed to seek and destroy pre-existing blood vessels within cancerous tumors by cutting off the tumor's blood supply.

Also presented was new pre-clinical data generated by Dr. Jin He at UT Southwestern Medical Center at Dallas demonstrating that radiation therapy significantly increases the anti-tumor activity of the Tarvacin(TM) equivalent named 3G4. In animals treated with 3G4 plus external beam radiation, tumor growth was reduced by 98% as compared with 85% for radiation therapy alone or 67% with 3G4 alone.